Exogenous administration of DLK1 ameliorates hepatic steatosis and regulates gluconeogenesis via activation of AMPK

International Journal of Obesity

Volumn 40, Issue 2, 2016, Pages 356-365

  Lee, Y H ^a   Yun, M R ^a   Kim, H M ^b   Jeon, B H ^a   Park, B C ^c   Lee, B W ^a   Kang, E S ^a   Lee, H C ^a   Park, Y W ^c   Cha, B S ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Chung Ang University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ANTIDIABETIC AGENT; DELTA LIKE 1 HOMOLOG PROTEIN; DIGESTIVE TRACT AGENT; FAT DROPLET; GLUCOSE; GLUCOSE 6 PHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; PROTEIN KINASE B; RECOMBINANT PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; DLK1 PROTEIN, MOUSE; NOTCH RECEPTOR; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME PHOSPHORYLATION; EPIDIDYMIS FAT; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL FATTY LIVER; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN TOLERANCE TEST; LIPID STORAGE; LIVER CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; TREATMENT DURATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID METABOLISM; LIVER; METABOLISM; NONALCOHOLIC FATTY LIVER; PATHOLOGY; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DISEASE MODELS, ANIMAL; GLUCONEOGENESIS; INJECTIONS, INTRAPERITONEAL; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID METABOLISM; LIVER; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84957838603     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2015.173     Document Type: Article

References (39)

1. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815-825.
2. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137: 216-233.
3. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007; 28: 339-363.
4. Ntziachristos P, Lim JS, Sage J, Aifantis I. From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell 2014; 25: 318-334.
5. Pajvani UB, Shawber CJ, Samuel VT, Birkenfeld AL, Shulman GI, Kitajewski J et al. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat Med 2011; 17: 961-967.
6. Pajvani UB, Qiang L, Kangsamaksin T, Kitajewski J, Ginsberg HN, Accili D. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med 2013; 19: 1054-1060.
7. Valenti L, Mendoza RM, Rametta R, Maggioni M, Kitajewski C, Shawber CJ et al. Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. Diabetes 2013; 62: 4052-4062.
8. Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008; 27: 5132-5137.
9. Lai EC. Notch signaling: control of cell communication and cell fate. Development 2004; 131: 965-973.
10. Baladron V, Ruiz-Hidalgo MJ, Nueda ML, Diaz-Guerra MJ, Garcia-Ramirez JJ, Bonvini E et al. dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats. Exp Cell Res 2005; 303: 343-359.
11. Nueda ML, Baladron V, Sanchez-Solana B, Ballesteros MA, Laborda J. The EGF-like protein dlk1 inhibits notch signaling and potentiates adipogenesis of mesenchymal cells. J Mol Biol 2007; 367: 1281-1293.
12. Bray SJ, Takada S, Harrison E, Shen SC, Ferguson-Smith AC. The atypical mammalian ligand Delta-like homologue 1 (Dlk1) can regulate Notch signalling in Drosophila. BMC Dev Biol 2008; 8: 11.
13. Wang Y, Sul HS. Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiation. Mol Cell Biol 2006; 26: 5421-5435.
14. Backliwal G, Hildinger M, Chenuet S, Wulhfard S, De Jesus M, Wurm FM. Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res 2008; 36: e96.
15. Seglen PO. Hepatocyte suspensions and cultures as tools in experimental carcinogenesis. J Toxicol Environ Health 1979; 5: 551-560.
16. Lee YH, Kim SH, Lee YJ, Kang ES, Lee BW, Cha BS et al. Transcription factor Snail is a novel regulator of adipocyte differentiation via inhibiting the expression of peroxisome proliferator-activated receptor gamma. Cell Mol Life Sci 2013; 70: 3959-3971.
17. Gesina E, Tronche F, Herrera P, Duchene B, Tales W, Czernichow P et al. Dissecting the role of glucocorticoids on pancreas development. Diabetes 2004; 53: 2322-2329.
18. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10: 143-156.
19. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMPactivated protein kinase. J Hepatol 2011; 54: 1214-1223.
20. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009; 9: 407-416.
21. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F et al. Insulinregulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423: 550-555.
22. Smas CM, Sul HS. Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 1993; 73: 725-734.
23. Wang Y, Kim KA, Kim JH, Sul HS. Pref-1, a preadipocyte secreted factor that inhibits adipogenesis. J Nutr 2006; 136: 2953-2956.
24. Sul HS. Minireview: Pref-1: role in adipogenesis and mesenchymal cell fate. Mol Endocrinol 2009; 23: 1717-1725.
25. Moon YS, Smas CM, Lee K, Villena JA, Kim KH, Yun EJ et al. Mice lacking paternally expressed Pref-1/Dlk1 display growth retardation and accelerated adiposity. Mol Cell Biol 2002; 22: 5585-5592.
26. Villena JA, Choi CS, Wang Y, Kim S, Hwang YJ, Kim YB et al. Resistance to high-fat diet-induced obesity but exacerbated insulin resistance in mice overexpressing preadipocyte factor-1 (Pref-1): a new model of partial lipodystrophy. Diabetes 2008; 57: 3258-3266.
27. Lee K, Villena JA, Moon YS, Kim KH, Lee S, Kang C et al. Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1). J Clin Invest 2003; 111: 453-461.
28. Ferron SR, Charalambous M, Radford E, McEwen K, Wildner H, Hind E et al. Postnatal loss of Dlk1 imprinting in stem cells and niche astrocytes regulates neurogenesis. Nature 2011; 475: 381-385.
29. da Rocha ST, Charalambous M, Lin S, Gutteridge I, Ito Y, Gray D et al. Gene dosage effects of the imprinted delta-like homologue 1 (dlk1/pref1) in development: implications for the evolution of imprinting. PLOS Genet 2009; 5: e1000392.
30. Mortensen SB, Jensen CH, Schneider M, Thomassen M, Kruse TA, Laborda J et al. Membrane-tethered delta-like 1 homolog (DLK1) restricts adipose tissue size by inhibiting preadipocyte proliferation. Diabetes 2012; 61: 2814-2822.
31. Charalambous M, Da Rocha ST, Radford EJ, Medina-Gomez G, Curran S, Pinnock SB et al. DLK1/PREF1 regulates nutrient metabolism and protects from steatosis. Proc Natl Acad Sci USA 2014; 111: 16088-16093.
32. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13: 251-262.
33. Falix FA, Aronson DC, Lamers WH, Gaemers IC. Possible roles of DLK1 in the Notch pathway during development and disease. Biochim Biophys Acta 2012; 1822: 988-995.
34. Huang CC, Chuang JH, Huang LL, Chou MH, Wu CL, Chen CM et al. The human Delta-like 1 homologue is implicated in the progression of liver fibrosis in biliary atresia. J Pathol 2004; 202: 172-179.
35. Zhu NL, Asahina K, Wang J, Ueno A, Lazaro R, Miyaoka Y et al. Hepatic stellate cellderived delta-like homolog 1 (DLK1) protein in liver regeneration. J Biol Chem 2012; 287: 10355-10367.
36. Labialle S, Marty V, Bortolin-Cavaille ML, Hoareau-Osman M, Pradere JP, Valet P et al. The miR-379/miR-410 cluster at the imprinted Dlk1-Dio3 domain controls neonatal metabolic adaptation. EMBO J 2014; 33: 2216-2230.
37. Li P, daY Oh, Bandyopadhyay G, Lagakos WS, Talukdar S, Osborn O et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med 2015; 21: 239-247.
38. Seo YY, Cho YK, Bae JC, Seo MH, Park SE, Rhee EJ et al. Tumor necrosis factoralpha as a predictor for the development of nonalcoholic fatty liver disease: a 4-year follow-up study. Endocrinol Metab (Seoul) 2013; 28: 41-45.
39. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-4761.